Same molecule. A different crystal.
Ritonavir’s Form II packed the same molecule into a more stable, less soluble crystal. Explore the difference between a chance first appearance and growth from an existing seed.
Enlarge for bigger labels, then swipe sideways →
Press Run a new draw. Repeat it to see chance first appearance, then try a seed. The unseeded chance is 2.5% in invented teaching units. The solubility comparison is 2.6 times in ethanol at 25°C for Form I relative to Form II. It does not predict a capsule’s dissolved fraction.
What this model assumes
This is a stochastic teaching toy, not a ritonavir process model. P(at least one new nucleus) = 1 − exp(−rate × exposure), using an invented Form II rate of 0.025 and invented exposure units. High push starts more schematic Form I cells; it does not change the Form II probability or fit a real nucleation rate. No units represent years, batch size, or an actual plant probability. Run a new draw samples a uniform random number; a supplied seed bypasses first nucleation. The growth slider deterministically replaces schematic Form I cells with Form II after its appearance, showing a possible solvent-mediated conversion, not measured growth rates or phase fractions. The initial cell population is a qualitative packing schematic, not measured nucleation kinetics. Solvent and temperature influence real nucleation, growth and transformation, but here the solvent selector changes only the separate literature solubility comparison. Wang 2021 reports Form I/Form II ≈2.6 in ethanol at 25°C and 3.9–5.7 in ethanol/water at 5°C, a composition-dependent range. No absolute dose, dissolution, bioavailability, clinical advice or capsule concentration is calculated. Degradation products, solvent composition, temperature cycling and real kinetic competition are omitted.
A form that is slow to appear can spread quickly once its seeds are present.
Ritonavir launched in 1996. In 1998, a previously unseen, less soluble crystal form caused manufacturing and formulation problems. Form I and Form II contain the same molecule in different conformations and crystal arrangements.
Form I can nucleate preferentially at high supersaturation. Form II has a more stable crystal structure but can have a long induction time before it first appears. Once a seed exists, nucleation no longer has to start from nothing.
The lattice below is a teaching schematic, not a molecular structure or a crystallization prediction. A random draw illustrates the first-appearance idea. Its rate, exposure units and growth rules are invented. Increasing exposure increases the chance in this toy model; it does not forecast years of real plant operation.
Wang and colleagues report Form I about 2.6 times as soluble as Form II in ethanol at 25°C. In ethanol/water at 5°C the reported ratio is 3.9–5.7, depending on composition. These are solvent-specific solubility comparisons, not percentages of a capsule absorbed or dissolved in the body.
The original facilities struggled to return to Form I after Form II appeared. Seeds can persist and promote further growth. This does not mean every batch in every solvent must always become Form II; temperature, solvent, supersaturation, impurities and processing history all matter.
After a Form II speck appears, why might returning to the old Form I process fail?
Taking a real process
beyond the lab?
Jon and I are building RARE Labs toward an autonomous pilot plant builder using AI and robotics. Join the waitlist for updates, and tell us what you’re trying to scale.
Go a little deeper.
- Wang et al., Pharmaceutical Research (2021)Molecular, Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir ↗
Form-dependent hydrogen bonding, crystallization behavior and solvent-specific solubility ratios of 2.6 and 3.9–5.7.
- Bauer et al., Pharmaceutical Research (2001)Ritonavir: an extraordinary example of conformational polymorphism ↗
Historical emergence and characterization of the less soluble Form II.
- European Medicines AgencyNorvir: scientific discussion ↗
Stable Form II, formulation and dissolution considerations.